Cannabis withdrawal in the United States: results from NESARC.
paper
Cited
Public
- Authors
- Hasin, Deborah S; Keyes, Katherine M; Alderson, Donald; Wang, Shuang; Aharonovich, Efrat; Grant, Bridget F
- Year
- 2008
- Journal
- The Journal of clinical psychiatry
- PMID
- 19012815
- DOI
- 10.4088/jcp.v69n0902
- PMCID
- PMC2777674
OBJECTIVE: Although cannabis is the most widely abused illicit drug, little is known about the prevalence of cannabis withdrawal and its factor structure, clinical validity, and psychiatric correlates in the general population. METHOD: National Epidemiologic Survey on Alcohol and Related Conditions participants were assessed, in 2001-2002, with structured in-person interviews covering substance history, DSM-IV Axis I and II disorders, and withdrawal symptoms after cessation of use. Of these, 2613 had been frequent cannabis users (> or = 3 times/week), and a "cannabis-only" subset (N = 1119) never binge-drank or used other drugs > or = 3 times/week. RESULTS: In the full sample and subset, 44.3% (SE = 1.19) and 44.2% (SE = 1.75), respectively, experienced > or = 2 cannabis withdrawal symptoms, while 34.4% (SE = 1.21) and 34.1% (SE = 1.76), respectively, experienced > or = 3 symptoms. The symptoms formed 2 factors, one characterized by weakness, hypersomnia, and psychomotor retardation and the second by anxiety, restlessness, depression, and insomnia. Both symptom types were associated with significant distress/impairment (p < .01), substance use to relieve/avoid cannabis withdrawal symptoms (p <.01), and quantity of cannabis use (among the cannabis-only users p < .05). Panic (p < .01) and personality (p > .01) disorders were associated with anxiety symptoms in both samples, family history of drug problems was associated with weakness symptoms in the subset (p = .01), and depression was associated with both sets of symptoms in the subset (p < or = .05). CONCLUSION: Cannabis withdrawal was prevalent and clinically significant among a representative sample of frequent cannabis users. Similar results in the subset without polysubstance abuse confirmed the specificity of symptoms to cannabis. Cannabis withdrawal should be added to DSM-V, and the etiology and treatment implications of cannabis withdrawal symptoms should be investigated.
No figures extracted from this document.
β Prev
21β33 of 33
| Name | Type |
|---|---|
| 53 men hospitalized cohort local | cohort |
| Adolescent males cohort local | cohort |
| adolescents | cohort |
| age | phenotype |
| age of onset | phenotype |
| Age of onset of cannabis use local | phenotype |
| alcohol | phenotype |
| alcohol dependence | phenotype |
| Alcohol Use Disorder | phenotype |
| alcohol withdrawal | phenotype |
| Another substance local | drug |
| antisocial personality disorder | phenotype |
| anxiety | phenotype |
| Anxiety/Depression factor local | phenotype |
| Anxiety/depression symptoms local | phenotype |
| Anxiety/depression withdrawal symptoms local | phenotype |
| Anxiety/Depression withdrawal symptoms local | phenotype |
| Anxiety withdrawal symptoms local | phenotype |
| Appetite changes local | phenotype |
| avoidant personality disorder | phenotype |
| Baby boomers | cohort |
| bad headaches local | phenotype |
| Better educated local | phenotype |
| cannabis dependence | phenotype |
| Cannabis disorders local | phenotype |
| Cannabis-only Subsample local | cohort |
| Cannabis-only users local | cohort |
| cannabis use | phenotype |
| cannabis use disorder | phenotype |
| Cannabis use quantity local | phenotype |
| Cannabis users without other substance abuse local | cohort |
| cannabis withdrawal | phenotype |
| Cannabis withdrawal symptom local | phenotype |
| Cannabis withdrawal symptoms (β₯3) local | phenotype |
| Census Bureau | cohort |
| clinical significance indicators local | phenotype |
| cocaine | phenotype |
| cocaine dependence criteria local | phenotype |
| cocaine withdrawal | phenotype |
| Delta-9 THC local | drug |
| demographic variables local | cohort |
| Dependence on other substances local | phenotype |
| dependent personality disorder | phenotype |
| depression | phenotype |
| Depression/anxiety local | phenotype |
| Depression/anxiety symptoms local | phenotype |
| Distress/Impairment local | phenotype |
| drug dependence | phenotype |
| DSM-IV cannabis abuse | phenotype |
| DSM-IV cannabis dependence | phenotype |
| Duration of heaviest use local | phenotype |
| Duration of heaviest use (<1 year) local | phenotype |
| education | phenotype |
| epilepsy | phenotype |
| Family history of drug problems local | phenotype |
| fatigue | phenotype |
| feeling weak or tired local | phenotype |
| Feeling weak/tired | phenotype |
| fever | phenotype |
| frequent cannabis-only users local | cohort |
| Frequent cannabis only users local | cohort |
| Frequent cannabis use | phenotype |
| frequent cocaine users local | cohort |
| Frequent Users local | cohort |
| Full group local | cohort |
| full sample | cohort |
| Full sample of frequent cannabis users local | cohort |
| full syndrome local | phenotype |
| generalized anxiety disorder | phenotype |
| general population | cohort |
| general population sample | cohort |
| hallucinations | phenotype |
| Healthy volunteers for research studies local | cohort |
| heavy drinking | phenotype |
| Hispanic | phenotype |
| histrionic personality disorder | phenotype |
| hypersomnia | phenotype |
| insomnia | phenotype |
| International population local | cohort |
| irritability | phenotype |
| Large nationally representative survey local | cohort |
| Less frequent cannabis users local | phenotype |
| major depressive disorder | phenotype |
| marijuana | phenotype |
| marital status | phenotype |
| mental retardation | phenotype |
| muscle aches | phenotype |
| muscle cramps local | phenotype |
| National Epidemiologic Survey on Alcohol and Related Conditions | cohort |
| nausea | phenotype |
| negative affect | phenotype |
| NESARC | cohort |
| NESARC sample local | cohort |
| NIAAA | cohort |
| obsessive-compulsive personality disorder | phenotype |
| Other cannabinoids local | drug |
| other drugs | drug |
| other substances | phenotype |
| panic disorder | phenotype |
| paranoid personality disorder | phenotype |
| Patients in substance abuse treatment local | cohort |
| Patients seeking treatment for marijuana problems local | cohort |
| personality disorders | phenotype |
| Physical component local | phenotype |
| Physical discomfort local | phenotype |
| Polysubstance abusers local | cohort |
| Polysubstance frequent cannabis users local | cohort |
| Poor outcome of dependence local | phenotype |
| Post-hospital marijuana use local | phenotype |
| Postural hypertension local | phenotype |
| psychiatric disorders | phenotype |
| psychiatric history | phenotype |
| Psychological component local | phenotype |
| Quantity of cannabis local | phenotype |
| race/ethnicity | phenotype |
| restlessness | phenotype |
| Reward properties of cannabis local | phenotype |
| runny eyes or nose local | phenotype |
| schizoid personality disorder | phenotype |
| sedatives | drug |
| sex | phenotype |
| shaking local | phenotype |
| Shorter duration of cannabis use local | phenotype |
| Significant distress or impairment local | phenotype |
| Sleep changes local | phenotype |
| Sleep disturbance | phenotype |
| Sleeping local | phenotype |
| stimulants | drug |
| Subsample local | cohort |
| Subset of frequent cannabis users that did not abuse other substances local | cohort |
| Subset of respondents local | cohort |
| substance use | phenotype |
| sweating | phenotype |
| tremor | phenotype |
| United States | cohort |
| Unmarried | phenotype |
| Untreated cannabis users local | cohort |
| Use of a substance to relieve/reduce cannabis withdrawal local | drug |
| vivid or unpleasant dreams local | phenotype |
| weakness local | phenotype |
| Weakness local | phenotype |
| Weakness factor local | phenotype |
| Weakness/fatigue local | phenotype |
| Weakness symptoms local | phenotype |
| Weakness withdrawal symptoms local | phenotype |
| withdrawal | phenotype |
| Withdrawal symptom local | phenotype |
| yawning | phenotype |
| younger cohort | cohort |
| Ξ9-THC | drug |
No uploaded files.
Not in any collection.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Alcohol and cannabis use for pain management: Translational findings of relative risks, benefits, and interactions. | Lee S et al. | β | 2025 | β |
| Daily Assessment of Positive and Negative Cannabis Use Expectancies in Young Adult Cannabis and Tobacco Co-Users: Differences by Sociodemographics, Mental Health Symptoms, and Possible Cannabis Use Disorder. | Romm KF et al. | β | 2025 | β |
| A systematic review of validity of US survey measures for assessing substance use and substance use disorders. | Tang Y et al. | β | 2024 | β |
| An Interpretable and Predictive Connectivity-Based Neural Signature forΒ ChronicΒ Cannabis Use. | Kulkarni KR et al. | β | 2023 | β |
| Cannabinoids as a Potential Alternative to Opioids in the Management of Various Pain Subtypes: Benefits, Limitations, and Risks. | Ang SP et al. | β | 2023 | β |
| Climbing the Evidence Pyramid: Dosing Considerations for Medical Cannabis in the Management of Chronic Pain. | Jugl S et al. | β | 2023 | β |
| Dimensionality and differential functioning of DSM-5 cannabis use disorder criteria in an online sample of adults with frequent cannabis use. | Shmulewitz D et al. | β | 2023 | β |
| Does tobacco dependence worsen cannabis withdrawal in people with and without schizophrenia-spectrum disorders? | Yeap ZJS et al. | β | 2023 | β |
| An exploration of multivariate symptom clusters of cannabis use disorder in young adults. | Howe LK et al. | β | 2022 | β |
| Are Borderline Personality Disorder Features Differentially Related to Pre-Incarceration Alcohol, Cannabis, Cocaine, and Opioid Dependence Among People Recently Incarcerated in Jail? | Loya JM et al. | β | 2022 | β |
| Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis. | Craft S et al. | β | 2022 | β |
| An interpretable connectivity-based decoding model for classification of chronic marijuana use | Kulkarni KR et al. | β | 2021 | β |
| Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings. | Kesner AJ et al. | β | 2021 | β |
| Progression of cannabis withdrawal symptoms in people using medical cannabis for chronic pain. | Coughlin LN et al. | β | 2021 | β |
| The emergency department care of the cannabis and synthetic cannabinoid patient: a narrative review. | Takakuwa KM et al. | β | 2021 | β |
| Cannabis and work: Need for more research. | Howard J et al. | β | 2020 | β |
| Cannabis Use, Cannabis Use Disorder, and Comorbid Psychiatric Illness: A Narrative Review. | Hasin D et al. | β | 2020 | β |
| Pharmacotherapies for Cannabis Use Disorders: Clinical Challenges and Promising Therapeutic Agents. | Nielsen S et al. | β | 2020 | β |
| Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. | Bahji A et al. | β | 2020 | β |
| Vaporized Cannabis Extracts Have Reinforcing Properties and Support Conditioned Drug-Seeking Behavior in Rats. | Freels TG et al. | β | 2020 | β |
| An Investigation of Neurochemical Changes in Chronic Cannabis Users. | Newman SD et al. | β | 2019 | β |
| Cannabis use disorders among adults in the United States during a time of increasing use of cannabis. | Compton WM et al. | β | 2019 | β |
| DSM-5 cannabis withdrawal syndrome: Demographic and clinical correlates in U.S. adults. | Livne O et al. | β | 2019 | β |
| Impact of Medical Marijuana Laws on State-Level Marijuana Use by Age and Gender, 2004-2013. | Mauro CM et al. | β | 2019 | β |
| Pharmacotherapies for cannabis dependence. | Nielsen S et al. | β | 2019 | β |
| A Survey of Payer Perspectives on Cannabis Use Disorder. | Kiselica AM et al. | β | 2018 | β |
| Cognitive and Mental Health Predictors of Withdrawal Severity During an Active Attempt to Cut Down Cannabis Use. | Cousijn J et al. | β | 2018 | β |
| Falling rates of marijuana dependence among heavy users. | Davenport S | β | 2018 | β |
| US Epidemiology of Cannabis Use and Associated Problems. | Hasin DS | β | 2018 | β |
| Cannabis use, attitudes, and legal status in the U.S.: A review. | Carliner H et al. | β | 2017 | β |
| The cannabis withdrawal syndrome: current insights. | Bonnet U et al. | β | 2017 | β |
| Cannabis Abusers Show Hypofrontality and Blunted Brain Responses to a Stimulant Challenge in Females but not in Males. | Wiers CE et al. | β | 2016 | β |
| Cannabis withdrawal and sleep: A systematic review of human studies. | Gates P et al. | β | 2016 | β |
| Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. | Hasin DS et al. | β | 2016 | β |
| Sex Differences in Cannabis Use and Effects: A Cross-Sectional Survey of Cannabis Users. | Cuttler C et al. | β | 2016 | β |
| Cannabis and psychopathology: The meandering journey of the last decade. | Ghosh A et al. | β | 2015 | β |
| Commonalities and Differences Across Substance Use Disorders: Phenomenological and Epidemiological Aspects. | Shmulewitz D et al. | β | 2015 | β |
| Nosologic Comparisons of DSM-IV and DSM-5 Alcohol and Drug Use Disorders: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. | Goldstein RB et al. | β | 2015 | β |
| Oral fluid cannabinoids in chronic frequent cannabis smokers during ad libitum cannabis smoking. | Lee D et al. | β | 2015 | β |
| Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013. | Hasin DS et al. | β | 2015 | β |
| The impact of gonadal hormones on cannabinoid dependence. | Marusich JA et al. | β | 2015 | β |
| The National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) Waves 1 and 2: review and summary of findings. | Hasin DS et al. | β | 2015 | β |
| Abstinence phenomena of chronic cannabis-addicts prospectively monitored during controlled inpatient detoxification: cannabis withdrawal syndrome and its correlation with delta-9-tetrahydrocannabinol and -metabolites in serum. | Bonnet U et al. | β | 2014 | β |
| Approach to cannabis use disorder in primary care: focus on youth and other high-risk users. | Turner SD et al. | β | 2014 | β |
| Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment. | Lee D et al. | β | 2014 | β |
| Cannabis withdrawal in patients with and without opioid dependence. | Chauchard E et al. | β | 2014 | β |
| Cannabis withdrawal syndrome: An important diagnostic consideration in adolescents presenting with disordered eating. | Chesney T et al. | β | 2014 | β |
| Do withdrawal-like symptoms mediate increased marijuana smoking in individuals treated with venlafaxine-XR? | Kelly MA et al. | β | 2014 | β |
| DSM-5 cannabis use disorder: a phenotypic and genomic perspective. | Agrawal A et al. | β | 2014 | β |
| Epidemiology of drinking, alcohol use disorders, and related problems in US ethnic minority groups. | Caetano R et al. | β | 2014 | β |
| Evaluation of sex differences in cannabinoid dependence. | Marusich JA et al. | β | 2014 | β |
| Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. | Johnston J et al. | β | 2014 | β |
| Medical marijuana laws and suicides by gender and age. | Anderson DM et al. | β | 2014 | β |
| Open-label pilot study of quetiapine treatment for cannabis dependence. | Mariani JJ et al. | β | 2014 | β |
| Pharmacotherapies for cannabis dependence. | Marshall K et al. | β | 2014 | β |
| The prevalence of cannabis withdrawal and its influence on adolescents' treatment response and outcomes: a 12-month prospective investigation. | Greene MC et al. | β | 2014 | β |
| Treatment of cannabis dependence using escitalopram in combination with cognitive-behavior therapy: a double-blind placebo-controlled study. | Weinstein AM et al. | β | 2014 | β |
| A genetic perspective on the proposed inclusion of cannabis withdrawal in DSM-5. | Verweij KJ et al. | β | 2013 | β |
| Cannabis withdrawal in chronic cannabis users with schizophrenia. | Boggs DL et al. | β | 2013 | β |
| Considering gender in cannabinoid research: a step towards personalized treatment of marijuana addicts. | Fattore L | β | 2013 | β |
| DSM-5 criteria for substance use disorders: recommendations and rationale. | Hasin DS et al. | β | 2013 | β |
| Marijuana, feijoada and the debate on drug legalization. | Crippa JA et al. | β | 2013 | β |
| Medical and recreational marijuana: commentary and review of the literature. | Wilkinson ST | β | 2013 | β |
| Neurological soft signs in non-psychotic patients with cannabis dependence. | Dervaux A et al. | β | 2013 | β |
| Organic and synthetic cannabinoid use in adolescents. | Bhatty S et al. | β | 2013 | β |
| Relief of cannabis withdrawal symptoms and cannabis quitting strategies in people with schizophrenia. | Koola MM et al. | β | 2013 | β |
| Reward-related brain response and craving correlates of marijuana cue exposure: a preliminary study in treatment-seeking marijuana-dependent subjects. | Goldman M et al. | β | 2013 | β |
| A comparative, developmental, and clinical perspective of neurobehavioral sexual dimorphisms. | Viveros MP et al. | β | 2012 | β |
| [Cannabis: Use and dependence]. | Dervaux A et al. | β | 2012 | β |
| Comparison of substance use milestones in cannabis- and cocaine-dependent patients. | Horey JT et al. | β | 2012 | β |
| Diagnostic criteria for cannabis withdrawal syndrome. | Gorelick DA et al. | β | 2012 | β |
| Dimensions and severity of marijuana consequences: development and validation of the Marijuana Consequences Questionnaire (MACQ). | Simons JS et al. | β | 2012 | β |
| Drug withdrawal-induced depression: serotonergic and plasticity changes in animal models. | Renoir T et al. | β | 2012 | β |
| Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. | CerdΓ‘ M et al. | β | 2012 | β |
| Quantifying the clinical significance of cannabis withdrawal. | Allsop DJ et al. | β | 2012 | β |
| The co-occurring use and misuse of cannabis and tobacco: a review. | Agrawal A et al. | β | 2012 | β |
| Cannabis in sport: anti-doping perspective. | Huestis MA et al. | β | 2011 | β |
| [Cannabis withdrawal syndrome in patients with cannabis dependence only, and in patients with cannabis and opioid dependence]. | Vorspan F et al. | β | 2011 | β |
| Marijuana dependence: not just smoke and mirrors. | Ramesh D et al. | β | 2011 | β |
| Personality disorders and the 3-year course of alcohol, drug, and nicotine use disorders. | Hasin D et al. | β | 2011 | β |
| Prolonged cannabinoid exposure alters GABA(A) receptor mediated synaptic function in cultured hippocampal neurons. | Deshpande LS et al. | β | 2011 | β |
| Sexually dimorphic effects of cannabinoid compounds on emotion and cognition. | Rubino T et al. | β | 2011 | β |
| The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. | Allsop DJ et al. | β | 2011 | β |
| The prevalence and clinical significance of inhalant withdrawal symptoms among a national sample. | Perron BE et al. | β | 2011 | β |
| Cannabis dependence in the San Francisco Family Study: age of onset of use, DSM-IV symptoms, withdrawal, and heritability. | Ehlers CL et al. | β | 2010 | β |
| Cannabis dimensionality: dependence, abuse and consumption. | Beseler CL et al. | β | 2010 | β |
| Cannabis withdrawal severity and short-term course among cannabis-dependent adolescent and young adult inpatients. | Preuss UW et al. | β | 2010 | β |
| Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers. | Levin KH et al. | β | 2010 | β |
| How important are sex differences in cannabinoid action? | Fattore L et al. | β | 2010 | β |
| Linkage analyses of cannabis dependence, craving, and withdrawal in the San Francisco family study. | Ehlers CL et al. | β | 2010 | β |
| Population-attributable fractions of Axis I and Axis II mental disorders for suicide attempts: findings from a representative sample of the adult, noninstitutionalized US population. | Bolton JM et al. | β | 2010 | β |
| Sociodemographic characteristics of cannabis smokers and the experience of cannabis withdrawal. | Copersino ML et al. | β | 2010 | β |
| Behavioural measures of frontal lobe function in a population of young social drinkers with binge drinking pattern. | Scaife JC et al. | β | 2009 | β |
| [Cyclical hyperemesis secondary to cannabis abuse]. | Ochoa-Mangado E et al. | β | 2009 | β |
| The analgesic potential of cannabinoids. | Elikkottil J et al. | β | 2009 | β |